On-demand treatment with the experimental oral therapy PHVS416 was found to quickly and effectively ease symptoms of swelling attacks for…
Articles by Marisa Wexler, MS
Over the months after a single treatment with the experimental gene-editing therapy NTLA-2002, nine of 10 people with hereditary…
Birth control pills can induce life-threatening swelling attacks in people with hereditary angioedema (HAE), according to a case report.
Ionis Pharmaceuticals has finished enrollment in a Phase 3 clinical trial testing the ability of its experimental therapy donidalorsen…
An experimental gene-editing therapy for hereditary angioedema (HAE), called NTLA-2002, has been administered to the first participant in the…
A pregnant woman with type 3 hereditary angioedema (HAE) had potential swelling attacks effectively controlled during both pregnancy and…
A woman with colon cancer developed angioedema as a side effect of treatment with an immune checkpoint inhibitor (ICI),…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to NTLA-2002, an experimental gene-editing…
The U.S. Food and Drug Administration (FDA) has given Intellia Therapeutics permission to open U.S. sites in its ongoing…
Astria Therapeutics has initiated a Phase 1b/2 trial called ALPHA-STAR to test STAR-0215, the company’s investigational therapy to prevent…